Tryptophan Hydroxylase Antibody / TPH1

Immunohistochemistry (FFPE): 1-2ug/ml for 30 minutes at RT

Phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH) comprise a small family of monooxygenases that use tetrahydropterine as a cofactor during the catabolism of aromatic L-amino acids. PAH, TH and TPH all contain catalytic domains with an amino-terminal regulatory domain and a short carboxy-terminal tetramerization domain. Each of these enzymes also contains a single ferrous iron atom, which is bound to two histidines and a glutamate, and is likely to be involved in the formation of the hydroxylating intermediate. TPH is both the first and rate-limiting-step in the biosynthesis of serotonin in the central nervous system and melatonin in the pineal gland. Alteration of TPH function may be a key factor in the pathology of several neuropsychiatric disorders associated with serotonin, including depression, aggression, alcoholism and schizophrenia. For instance, LDOPA, which is used as a common therapy for Parkinson s disease (PD) patients, inhibits TPH function which, subsequently, is thought to contribute to the onset of depression in PD patients.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Recombinant full-length human TPH1 protein was used as the immunogen for the TPH1 antibody.

This TPH1 antibody is available for research use only.

Cytoplasm, Nucleus

Protein A/G affinity

P17752